Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension. 2009

Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
Istanbul Medical Faculty, Bone Marrow Transplantation Unit, Department of Pediatric Haematology and Oncology, Istanbul University, Istanbul, Turkey. hakekmekci@yahoo.com

The aim of the present study is to determine and correlate adiponectin, homocysteine, nitric oxide, and ADP-induced platelet aggregation levels in untreated patients with essential hypertension and healthy individuals. A total of 36 individuals, 23 untreated patients with essential hypertension and 13 healthy individuals, were included in the scope of this study. Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum adiponectin and TNF-alpha levels. The levels of serum homocysteine were measured by using competitive chemiluminescent enzyme immunoassay. Serum concentrations of hsCRP were measured by the Nephelometer. Plasma nitrite, nitrate, and total nitric oxide (NOx) levels were determined by colorimetric method. Homocysteine and hsCRP levels in patients with essential hypertension were found to be significantly higher than those in the control group (P = 0.02, P = 0.001, respectively). The average platelet aggregation levels in patient group were higher than control group, but there were no statistically significant differences between them (P > 0.05). In addition, in patients with essential hypertension adiponectin and nitrite levels are significantly lower than control group (P < 0.001, P = 0.045, respectively). We have also found significant correlations between nitrite-platelet aggregation amplitude, nitrite-platelet aggregation slope, nitrite-adiponectin, homocysteine-platelet aggregation amplitude, and sistolic blood pressure-platelet aggregation amplitude levels (r = -0.844; P < 0.001, r = -0.680; P = 0.011, r = 0.454; P = 0.05, r = 0.414; P = 0.05, r = 0.442; P = 0.035, respectively). Increased homocysteine and decreased adiponectin serum levels in patients with essential hypertension correlate well with changes in ADP-induced conventional platelet aggregation. This association may potentially contribute to future thrombus formation and higher risks for cardiovascular events in hypertensive patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D005260 Female Females
D006710 Homocysteine A thiol-containing amino acid formed by a demethylation of METHIONINE. 2-amino-4-mercaptobutyric acid,Homocysteine, L-Isomer,2 amino 4 mercaptobutyric acid,Homocysteine, L Isomer,L-Isomer Homocysteine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D052242 Adiponectin A 30-kDa COMPLEMENT C1Q-related protein, the most abundant gene product secreted by FAT CELLS of the white ADIPOSE TISSUE. Adiponectin modulates several physiological processes, such as metabolism of GLUCOSE and FATTY ACIDS, and immune responses. Decreased plasma adiponectin levels are associated with INSULIN RESISTANCE; TYPE 2 DIABETES MELLITUS; OBESITY; and ATHEROSCLEROSIS. ACRP30 Protein,Adipocyte Complement-Related Protein 30-kDa,Adipocyte, C1q and Collagen Domain Containing Protein,Adipose Most Abundant Gene Transcript 1,apM-1 Protein,Adipocyte Complement Related Protein 30 kDa,apM 1 Protein

Related Publications

Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
January 1990, European journal of clinical pharmacology,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
January 1993, Clinical therapeutics,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
January 1988, European journal of clinical pharmacology,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
January 2002, Kardiologiia,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
January 2013, Terapevticheskii arkhiv,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
August 2010, Journal of Zhejiang University. Science. B,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
November 2018, BioFactors (Oxford, England),
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
August 2005, Croatian medical journal,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
June 1985, Clinical pharmacology and therapeutics,
Hakan Ekmekçi, and Ozlem Balci Ekmekçi, and Serap Erdine, and Hüseyin Sönmez, and Yusup Ataev, and Zeynep Oztürk, and Ilknur Işler Bütün, and Ciğdem Gürel, and Mine Kucur, and Nurver Turfaner, and Turgut Ulutin, and Sevim Purisa, and Vural Ali Vural
March 2003, Renal failure,
Copied contents to your clipboard!